229 related articles for article (PubMed ID: 34514376)
1. Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.
Castillo AMM; Vu TT; Liva SG; Chen M; Xie Z; Thomas J; Remaily B; Guo Y; Subrayan UL; Costa T; Helms TH; Irby DJ; Kim K; Owen DH; Kulp SK; Mace TA; Phelps MA; Coss CC
JCSM Rapid Commun; 2021; 4(2):232-244. PubMed ID: 34514376
[TBL] [Abstract][Full Text] [Related]
2. Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia.
Vu TT; Kim K; Manna M; Thomas J; Remaily BC; Montgomery EJ; Costa T; Granchie L; Xie Z; Guo Y; Chen M; Castillo AMM; Kulp SK; Mo X; Nimmagadda S; Gregorevic P; Owen DH; Ganesan LP; Mace TA; Coss CC; Phelps MA
Pharmacol Res; 2024 Jan; 199():107048. PubMed ID: 38145833
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance.
Turner DC; Kondic AG; Anderson KM; Robinson AG; Garon EB; Riess JW; Jain L; Mayawala K; Kang J; Ebbinghaus SW; Sinha V; de Alwis DP; Stone JA
Clin Cancer Res; 2018 Dec; 24(23):5841-5849. PubMed ID: 29891725
[TBL] [Abstract][Full Text] [Related]
4. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients.
Li H; Li B; Wang X; Zhang H; Wang C; Fan B; Wang L
Nutrition; 2024 Apr; 124():112462. PubMed ID: 38663128
[TBL] [Abstract][Full Text] [Related]
5. Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients.
Ohuchi M; Yagishita S; Jo H; Akagi K; Inaba Higashiyama R; Masuda K; Shinno Y; Okuma Y; Yoshida T; Goto Y; Horinouchi H; Makino Y; Yamamoto N; Ohe Y; Hamada A
Lung Cancer; 2022 Nov; 173():35-42. PubMed ID: 36116168
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. High levels of modified ceramides are a defining feature of murine and human cancer cachexia.
Morigny P; Zuber J; Haid M; Kaltenecker D; Riols F; Lima JDC; Simoes E; Otoch JP; Schmidt SF; Herzig S; Adamski J; Seelaender M; Berriel Diaz M; Rohm M
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1459-1475. PubMed ID: 33090732
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
9. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
10. Antibody Drug Clearance: An Underexplored Marker of Outcomes with Checkpoint Inhibitors.
Guo Y; Remaily BC; Thomas J; Kim K; Kulp SK; Mace TA; Ganesan LP; Owen DH; Coss CC; Phelps MA
Clin Cancer Res; 2024 Mar; 30(5):942-958. PubMed ID: 37921739
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of epidermal growth factor receptor suppresses parathyroid hormone-related protein expression in tumours and ameliorates cancer-associated cachexia.
Weber BZC; Agca S; Domaniku A; Bilgic SN; Arabaci DH; Kir S
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1582-1594. PubMed ID: 35373517
[TBL] [Abstract][Full Text] [Related]
12. Obesity worsens mitochondrial quality control and does not protect against skeletal muscle wasting in murine cancer cachexia.
Cardaci TD; VanderVeen BN; Bullard BM; McDonald SJ; Unger CA; Enos RT; Fan D; Velázquez KT; Frizzell N; Spangenburg EE; Murphy EA
J Cachexia Sarcopenia Muscle; 2024 Feb; 15(1):124-137. PubMed ID: 38062911
[TBL] [Abstract][Full Text] [Related]
13. The p97-Nploc4 ATPase complex plays a role in muscle atrophy during cancer and amyotrophic lateral sclerosis.
Re Cecconi AD; Barone M; Gaspari S; Tortarolo M; Bendotti C; Porcu L; Terribile G; Piccirillo R
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2225-2241. PubMed ID: 35611892
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour-bearing mice.
Brown JL; Rosa-Caldwell ME; Lee DE; Blackwell TA; Brown LA; Perry RA; Haynie WS; Hardee JP; Carson JA; Wiggs MP; Washington TA; Greene NP
J Cachexia Sarcopenia Muscle; 2017 Dec; 8(6):926-938. PubMed ID: 28845591
[TBL] [Abstract][Full Text] [Related]
15. A novel orthotopic mouse model replicates human lung cancer cachexia.
van de Worp WRPH; Theys J; González AS; van der Heyden B; Verhaegen F; Hauser D; Caiment F; Smeets HJM; Schols AMWJ; van Helvoort A; Langen RCJ
J Cachexia Sarcopenia Muscle; 2023 Jun; 14(3):1410-1423. PubMed ID: 37025071
[TBL] [Abstract][Full Text] [Related]
16. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.
Chiappalupi S; Sorci G; Vukasinovic A; Salvadori L; Sagheddu R; Coletti D; Renga G; Romani L; Donato R; Riuzzi F
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):929-946. PubMed ID: 32159297
[TBL] [Abstract][Full Text] [Related]
17. The importance of FcRn in neuro-immunotherapies: From IgG catabolism,
Dalakas MC; Spaeth PJ
Ther Adv Neurol Disord; 2021; 14():1756286421997381. PubMed ID: 33717213
[TBL] [Abstract][Full Text] [Related]
18. Administration of adiponectin receptor agonist AdipoRon relieves cancer cachexia by mitigating inflammation in tumour-bearing mice.
Massart IS; Kouakou AN; Pelet N; Lause P; Schakman O; Loumaye A; Abou-Samra M; Deldicque L; Bindels LB; Brichard SM; Thissen JP
J Cachexia Sarcopenia Muscle; 2024 Apr; ():. PubMed ID: 38572511
[TBL] [Abstract][Full Text] [Related]
19. Cachectic Cancer Patients: Immune to Checkpoint Inhibitor Therapy?
Coss CC; Clinton SK; Phelps MA
Clin Cancer Res; 2018 Dec; 24(23):5787-5789. PubMed ID: 30018117
[TBL] [Abstract][Full Text] [Related]
20. Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human
Low BE; Christianson GJ; Lowell E; Qin W; Wiles MV
MAbs; 2020; 12(1):1829334. PubMed ID: 33025844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
